Research Guide · AA-TRZ-2026-52K
Tirzepatide
Dual GIP / GLP-1 Receptor Agonist Sequence
CAS
2023788-19-2
Mol. Weight
4813.5 g/mol
Purity
99.92%
Format
20mg Vial
Overview
Tirzepatide is a 39-amino acid dual GIP and GLP-1 receptor co-agonist — the compound that validated the multi-agonist approach in metabolic research, with one of the largest clinical literature bases of any modern peptide.
Mechanism of Action
Simultaneous engagement of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors produces synergistic incretin signaling in cell culture and in-vivo models, with downstream effects on insulin secretion, glucagon suppression, and gastric-emptying kinetics.
Dosing-Study Summary
SURPASS clinical program
5 / 10 / 15 mg, subcutaneous, weekly
Dose-dependent glycemic and body-weight endpoints exceeding single-agonist comparators across published arms
In-vitro incretin receptor assays
Nanomolar range
Dual receptor engagement with biased signaling distinct from GLP-1 alone (PubMed #34215024)
Doses shown are reported in cited preclinical / clinical literature for research reference only — not usage recommendations.
Storage & Handling
Store lyophilized at -20°C protected from light. Reconstitute with bacteriostatic water; refrigerate at 2–8°C. Avoid vigorous agitation — long incretin peptides are shear-sensitive.
Citations
This guide summarizes published scientific literature for laboratory research reference. Alpha Amino compounds are for research use only — not for human or animal consumption. Nothing here constitutes medical or dosing advice.